7.3 Pharmacological Modulation: Propranolol, Oxandrolone, Growth Hormone, and Exercise Therapy
Key Takeaways
- Pharmacological anti-catabolic therapy is required in severe burns because nutritional support alone cannot overcome the massive 10- to 50-fold catecholamine- and glucocorticoid-driven hypermetabolic state.
- Propranolol, a non-selective beta-1 and beta-2 adrenergic antagonist, reduces resting energy expenditure by 15%–25%, lowers cardiac workload, blunts peripheral lipolysis, reverses hepatic steatosis, and preserves lean body mass; it is titrated to reduce baseline resting heart rate by 15% to 20%.
- Oxandrolone, an oral synthetic anabolic androgenic steroid with high anabolic activity and minimal androgenicity, significantly accelerates donor site re-epithelialization, preserves lean body mass, and shortens hospital length of stay (standard adult dose: 10 mg PO BID; pediatrics: 0.1 mg/kg PO BID).
- Recombinant Human Growth Hormone (rhGH) is effective for linear growth and wound healing in pediatric burns, but is strictly avoided in critically ill adult burn patients due to clinical trial evidence demonstrating doubled mortality from severe hyperglycemia, infection, and multi-organ failure.
- Non-pharmacological metabolic interventions—including maintaining an ambient room temperature of 85°F–90°F (29°C–32°C) to eliminate shivering thermogenesis and instituting early progressive resistive exercise therapy—synergize with pharmacotherapy to preserve functional myofibrillar mass.
7.3 Pharmacological Modulation: Propranolol, Oxandrolone, Growth Hormone, and Exercise Therapy
Core Knowledge: Providing optimal enteral nutrition is essential, but nutritional support alone is insufficient to halt the hypercatabolic storm of severe thermal trauma. Exogenous calories without metabolic modulation often lead to excessive adipose deposition and fatty liver rather than myofibrillar muscle preservation. Pharmacological and environmental modulation blunts hyperadrenergic signaling, suppresses proteolysis, and stimulates net protein synthesis. Certified Burn Registered Nurses (CBRN) play a central role in initiating, titrating, and monitoring anti-catabolic agents including propranolol and oxandrolone, while maintaining thermal neutrality and integrating progressive resistive exercise.
1. Rationale for Anti-Catabolic and Anabolic Pharmacotherapy
In burns $\ge 40%$ TBSA, the neuroendocrine drive is so intense that skeletal muscle continues to break down even in the presence of massive positive caloric balance. Pharmacological agents target the specific biochemical pathways mediating this catabolic response:
PHARMACOLOGICAL & METABOLIC TARGETS IN BURNS
┌──────────────────────────────────────────────┬───────────────────────────────────────────┐
│ Pathophysiological Driver │ Therapeutic Countermeasure │
├──────────────────────────────────────────────┼───────────────────────────────────────────┤
│ Massive Catecholamine Surge (Epi/Norepi) │ PROPRANOLOL (Non-selective β1/β2 Blockade)│
│ Severe Glucocorticoid Proteolysis & Cachexia │ OXANDROLONE (Synthetic Anabolic Androgen) │
│ Depressed Linear Growth & Wound Hypoplasia │ RECOMBINANT GROWTH HORMONE (Pediatrics) │
│ Shivering Thermogenesis & Cold Stress │ THERMONEUTRAL AMBIENT ROOM (85°F–90°F) │
│ Sarcopenia & Disuse Myofibrillar Atrophy │ PROGRESSIVE RESISTIVE EXERCISE THERAPY │
└──────────────────────────────────────────────┴───────────────────────────────────────────┘
2. Propranolol: Non-Selective Beta-Adrenergic Antagonism
Propranolol is a non-selective beta-1 and beta-2 adrenergic receptor antagonist that acts as the primary pharmacological blunt against the 10- to 50-fold circulating catecholamine flood.
MECHANISMS OF PROPRANOLOL IN BURNS
┌─────────────────────────────────────────────────────────────────────────────┐
│ PROPRANOLOL (β1 & β2 Blockade) │
└──────────────────────────────────────┬──────────────────────────────────────┘
│
┌───────────────────────────────┼───────────────────────────────┐
▼ ▼ ▼
┌──────────────────────────────┐┌──────────────────────────────┐┌──────────────────────────────┐
│ CARDIOVASCULAR ││ ADIPOSE TISSUE ││ SKELETAL MUSCLE │
│ • Decreases resting HR by ││ • Blocks hormone-sensitive ││ • Inhibits intracellular │
│ 15% to 20% ││ lipase (HSL) ││ proteolytic enzymes │
│ • Lowers myocardial oxygen ││ • Reduces circulating FFA ││ • Improves net fractional │
│ consumption (MVO2) ││ flux to liver ││ protein synthesis │
│ • Decreases overall REE ││ • Reverses hepatic steatosis ││ • Preserves lean body mass │
│ by 15% to 25% ││ and hepatomegaly ││ and muscle strength │
└──────────────────────────────┘└──────────────────────────────┘└──────────────────────────────┘
Clinical Benefits of Propranolol
- Reduces Resting Energy Expenditure: Blunts whole-body metabolic rate by 15% to 25%, dramatically lowering caloric demand.
- Myocardial Protection: Reduces rate-pressure product and myocardial work without compromising central cardiac output in the flow phase.
- Reversal of Hepatic Steatosis: By inhibiting peripheral lipolysis, propranolol shuts off the flood of free fatty acids entering the liver, shrinking fatty liver infiltration and reducing liver size by up to 40% within weeks.
- Enhanced Wound Healing: Beta-2 blockade promotes keratinocyte migration and accelerates re-epithelialization of partial-thickness burns and split-thickness donor sites.
Dosing and Nursing Titration
- Initiation: Begun during the early flow phase (post-resuscitation, typically >48 to 72 hours post-burn) once intravascular volume is stabilized and the patient exhibits persistent hyperdynamic tachycardia.
- Starting Dose: Adult: 10 to 20 mg PO every 6 to 8 hours (or IV infusion if enteral absorption is erratic); pediatric: 0.5 to 1.0 mg/kg/day divided q6–8h.
- Titration Goal: Titrate upward to achieve a 15% to 20% reduction in resting heart rate from baseline (e.g., reducing a resting flow-phase heart rate from 135 bpm down to 105–110 bpm in adults).
- Nursing Safety Alerts:
- Continuously monitor heart rate and blood pressure prior to each dose.
- Hold and notify provider if heart rate drops below 60 bpm in adults (or age-appropriate pediatric threshold) or if MAP $<65\text{ mmHg}$.
- Caution in patients with reactive airway disease (asthma, severe inhalation injury) due to potential beta-2 bronchospasm.
- Never discontinue propranolol abruptly; sudden cessation triggers a rebound adrenergic crisis.
3. Oxandrolone: Synthetic Anabolic Androgenic Steroid
Oxandrolone is an oral synthetic testosterone derivative with modified chemical structure (17-alpha-methylated) that provides high anabolic activity with minimal androgenic side effects (anabolic-to-androgenic ratio of approximately 10:1 to 13:1).
OXANDROLONE CLINICAL EFFICACY
┌─────────────────────────────────────────────────────────────────────────────┐
│ OXANDROLONE (10 mg PO BID in Adults) │
├─────────────────────────────────────────────────────────────────────────────┤
│ • Accelerates Donor Site Healing: Shortens time to re-epithelialization │
│ by 2 to 3 days (p < 0.001), allowing faster re-harvesting of donor sites. │
│ • Preserves Lean Body Mass (LBM): Increases intracellular protein synthesis │
│ and decreases urinary nitrogen wasting. │
│ • Shortens Length of Hospital Stay: Significantly reduces acute burn ICU │
│ and total hospital days. │
│ • Promotes Long-Term Weight Gain: Accelerates restoration of functional │
│ body mass during acute recovery and outpatient rehabilitation. │
└─────────────────────────────────────────────────────────────────────────────┘
Dosing, Administration, and Monitoring
- Standard Adult Dosing: 10 mg PO twice daily (BID).
- Pediatric Dosing: 0.1 mg/kg PO twice daily (BID).
- Timing: Initiated once the patient enters the flow phase and enteral access is established; frequently continued throughout acute hospitalization and for 6 to 12 months post-discharge during intensive rehabilitation.
- Nursing Surveillance & Laboratory Monitoring:
- Hepatic Function Tests (LFTs): Baseline and weekly monitoring of AST, ALT, alkaline phosphatase, and total bilirubin. Mild transaminase elevations (2–3x normal) are common; hold therapy if transaminases rise $>5\times$ upper limit of normal or if clinical jaundice develops.
- Virilization Monitoring: Monitor female patients and prepubertal children for signs of androgen excess (hirsutism, acne, clitoromegaly, deepening of the voice).
- Fluid Retention: Monitor for peripheral edema in patients with borderline cardiac function.
4. Recombinant Human Growth Hormone (rhGH) & IGF-1
Recombinant human Growth Hormone (rhGH) stimulates the transcription of Insulin-Like Growth Factor 1 (IGF-1) in the liver and peripheral tissues, driving cellular proliferation and amino acid uptake.
GROWTH HORMONE IN BURNS: PEDIATRIC VS. ADULT CONTRAST
┌────────────────────────────────────────┬────────────────────────────────────────┐
│ PEDIATRIC BURNS │ CRITICAL ADULT BURNS │
├────────────────────────────────────────┼────────────────────────────────────────┤
│ • Safe and highly effective │ • CONTRAINDICATED / STRICT CAUTION │
│ • Restores post-burn linear growth │ • Landmark clinical trials proved │
│ • Accelerates donor site healing │ rhGH DOUBLES MORTALITY in critically │
│ • Preserves bone mineral density │ ill adults │
│ • Enhances immune cell function │ • Driven by severe hyperglycemia, │
│ • Dose: 0.05–0.2 mg/kg/day SubQ │ septic shock, and multi-organ failure│
└────────────────────────────────────────┴────────────────────────────────────────┘
[!CAUTION] Recombinant human Growth Hormone (rhGH) must NEVER be routinely administered to critically ill adult burn patients in the ICU. Multicenter randomized trials demonstrated a 2-fold increase in adult ICU mortality associated with high-dose rhGH, mediated by lethal stress hyperglycemia, impaired neutrophil phagocytosis, and hyperosmolar complications. In adults, oxandrolone is the anabolic agent of choice.
5. Non-Pharmacological Strategies: Thermoneutrality & Resistive Exercise
Pharmacotherapy must be paired with environmental and physical interventions to achieve complete metabolic control.
THERMAL AND EXERCISE MODULATION PROTOCOLS
┌─────────────────────────────────────────────────────────────────────────────┐
│ 1. THERMONEUTRAL AMBIENT ENVIRONMENT: │
│ • Ambient Burn Room Temperature Target: 85°F to 90°F (29°C to 32°C) │
│ • Relative Humidity Target: 40% to 50% │
│ • Rationale: Eliminates evaporative cooling and shivering thermogenesis, │
│ which otherwise spikes metabolic rate and VO2 by an additional 50–100%.│
├─────────────────────────────────────────────────────────────────────────────┤
│ 2. PROGRESSIVE RESISTIVE EXERCISE TRAINING (PRET): │
│ • Initiate early in ICU stay as soon as grafts are adherent (Post-op 4–7)│
│ • Combines resistive load training (bands/weights) with aerobic cycling. │
│ • Cellular Effect: Mechanotransduction stimulates myofibrillar protein │
│ synthesis, directing ingested amino acids into functional muscle mass │
│ rather than visceral fat. │
└─────────────────────────────────────────────────────────────────────────────┘
A 28-year-old female with a 45% TBSA flame burn on post-burn day 5 is in the hypermetabolic flow phase. Her baseline resting heart rate is consistently 135 bpm, blood pressure is 128/72 mmHg, and core body temperature is 38.2°C. The multidisciplinary team plans to initiate propranolol to modulate hypermetabolism. What is the standard target parameter for propranolol titration in this patient?
A burn nurse is administering oxandrolone 10 mg PO twice daily to an adult patient recovering from a 40% TBSA burn. Which clinical benefit is most directly supported by clinical trial evidence for this medication?
Why is recombinant human Growth Hormone (rhGH) strictly avoided in the routine management of critically ill adult burn patients in the intensive care unit?